INVVY - Insys: Will The Pipeline Drive Future Growth?
Insys (INSY) reported Q4 revenue of $31.5 million and eps of -$0.61. The company missed on revenue by $2.5 million and missed on eps by $0.47. However, the quarter was not all bad for Insys.
Revenue Appears To Be Stabilizing
Insys manufactures and markets two main drugs - subsys and syndros. Subsys delivers fentanyl, an opioid analgesic used for the treatment of breakthrough pain caused by cancer ("BTCP") in opioid-tolerant patients. Syndros oral solution is approved for the second-line treatment of chemotherapy-induced nausea and vomiting ("CINV") and anorexia associated with weight loss in